Visionary Holdings Launches Toronto-Based Joint Venture to Drive Global Commercialization of Innovative Stem Cell Therapy for Diabetes Remission, Targeting a $150 Billion Market Opportunity

Rhea-AI Summary

Visionary Holdings (Nasdaq: GV) announced on October 22, 2025 a strategic cooperation with Jiangsu Yike to form Visionary Yike Stemcell Technologies, a Canada-based joint venture focused on stem cell R&D, clinical application, manufacturing and global commercialization.

GV will hold 85% and Yike 15%. The JV may be headquartered at GV's Toronto property (95–105 Moatfield Drive, ~40,000 sqm) and will explore cleanrooms, low-temperature biostorage, and production infrastructure. Initial targets include stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics with a stated focus on Type 1 and Type 2 diabetes; clinical evidence so far is described as preclinical/exploratory. Development is subject to regulatory, financing, and operational planning.

Positive

• GV equity control of 85% in the joint venture
• Planned HQ on GV's ~40,000 sqm Toronto property
• JV aims for vertical integration across R&D, trials, manufacturing, sales

Negative

• Clinical evidence for diabetes described only as preclinical/exploratory
• Commercialization and facility development subject to regulatory approval
• Project outcomes contingent on financing and operational planning

TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercialization worldwide.

Under the agreement, GV and Yike will leverage their respective strengths in global commercialization and regenerative medicine with the goal of advancing the development of stem cell manufacturing and R&D hub in North America. GV's property complex at 95–105 Moatfield Drive, Toronto, Ontario (former IBM headquarters), which comprises more than 40,000 square meters of space, is being considered as the intended headquarters for the joint venture. The parties are assessing the feasibility of developing cleanrooms, low-temperature biostorage, and related infrastructures that could support future cell resource and production operations.

The joint venture will initially focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics and intervention models, leveraging Yike's proprietary platform and GV's global market infrastructure. Both parties will contribute resources and share potential benefits in proportion to their equity stakes, with GV holding 85% and Yike holding 15%. In particular, the joint venture intend to advance the clinical application and commercialization of Yike's breakthrough stem cell technologyincluding both Type 1 and Type 2 diabetes, which has shown early scientific promise in preclinical and exploratory studies.  

Through this collaboration, the parties plan to create a vertically integrated regenerative medicine enterprise encompassing R&D, trials, manufacturing, and global sales, which could enhance GV's long-term positioning in the North American stem cell sector.

Xiyong Hou, CEO of Visionary Holdings, commented:

"The establishment of Visionary Yike Stemcell Technologies marks a transformative milestone for GV's global health strategy. This new company is expected to be located at GV's Toronto property, which the parties believe has the potential to support future development of regenerative medicine operation and long-term value creation. The facility may be developed over time into an integrated campus supporting R&D, manufacturing, and commercialization activities, subject to regulatory, financing and operational planning.

By combining Yike's proprietary stem cell and anti-aging technologies with GV's international commercialization network, we aim to deliver innovative, science-based solutions that aim to improve human health and longevity. This collaboration reflects our continued commitment to global innovation and value creation for shareholders."

Building on the global license agreement for Yike's stem cell technology announced earlier this month, this new joint venture is expected to serve as the operational and commercialization platform for that breakthrough technology — representing a future step in GV's strategic expansion into the healthcare and life sciences sector.

About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

About Yike Regenerative Medicine
Jiangsu Yike Regenerative Medicine ( http://jsyk.club) is a high-tech enterprise specializing  in regenerative medicine and precision anti-aging technologies. The company operates across multiple platforms, including genetic engineering, stem cell research, and immune cell applications. Yike co-established the Institute of Aging and Regenerative Medicine with Jinan University, and holds numerous international patents and software copyrights. It also  maintains ISO9001 and cGMP certifications, underscoring its commitment to quality and compliance.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings 

 

View original content:https://www.prnewswire.com/news-releases/visionary-holdings-launches-toronto-based-joint-venture-to-drive-global-commercialization-of-innovative-stem-cell-therapy-for-diabetes-remission-targeting-a-150-billion-market-opportunity-302590980.html

SOURCE Visionary Holdings

FAQ

What did Visionary Holdings (GV) announce on October 22, 2025?

GV announced a strategic cooperation with Yike to form Visionary Yike Stemcell Technologies, a Canada-based joint venture for stem cell commercialization.

How much ownership will GV hold in the new joint venture (GV)?

GV will hold 85% ownership while Yike will hold 15%.

Where will the Visionary Yike Stemcell Technologies headquarters likely be located?

The parties intend the HQ to be at GV's Toronto property, 95–105 Moatfield Drive, which is about 40,000 sqm.

What therapeutic areas will the GV joint venture initially target?

The JV will initially focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics, including work on Type 1 and Type 2 diabetes.

What development steps are required before commercialization by GV (GV)?

Commercialization depends on successful R&D, regulatory approvals, financing, and operational planning for manufacturing and storage facilities.

Is the diabetes evidence for Yike's technology clinical or preclinical?

The announcement describes the diabetes results as preclinical and exploratory, not as completed clinical trial outcomes.